Referral patterns and attrition rate for germline testing in pancreatic cancer (PC) patients. Read more about Referral patterns and attrition rate for germline testing in pancreatic cancer (PC) patients.
Phase 2 trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): Clinical outcomes and biomarker analyses. Read more about Phase 2 trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): Clinical outcomes and biomarker analyses.
Pre-clinical development of TNB-383B, a fully human T-cell engaging bispecific antibody targeting BCMA for the treatment of multiple myeloma. Read more about Pre-clinical development of TNB-383B, a fully human T-cell engaging bispecific antibody targeting BCMA for the treatment of multiple myeloma.
Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors. Read more about Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors.
Effect of risk communication on anxiety, breast cancer worry and risk perception in women at high risk of breast cancer. Read more about Effect of risk communication on anxiety, breast cancer worry and risk perception in women at high risk of breast cancer.
A breast cancer risk model as a predictor of interval cancer rate and tumor characteristics. Read more about A breast cancer risk model as a predictor of interval cancer rate and tumor characteristics.
Impact of patient reported functional limitation on overall survival in older adults undergoing autologous hematopoietic cell transplant (AutoHCT). Read more about Impact of patient reported functional limitation on overall survival in older adults undergoing autologous hematopoietic cell transplant (AutoHCT).
Efficacy and cost-effectiveness of clofarabine with high-dose cytarabine for treatment of relapsed/refractory acute myeloid leukemia (R/R AML). Read more about Efficacy and cost-effectiveness of clofarabine with high-dose cytarabine for treatment of relapsed/refractory acute myeloid leukemia (R/R AML).
Hyperpolarized C-13 pyuvate metabolic MR imaging of solid tumor liver metastases as a biomarker of PI3K/mTOR pathway activity. Read more about Hyperpolarized C-13 pyuvate metabolic MR imaging of solid tumor liver metastases as a biomarker of PI3K/mTOR pathway activity.
Post hoc exploratory analysis of two phase 2 trials of quizartinib monotherapy in patients (pts) with FLT3 -ITD–mutated (mu) relapsed/refractory (R/R) AML with or without prior 1st-generation FLT3 tyrosine kinase inhibitors (TKI) treatment. Read more about Post hoc exploratory analysis of two phase 2 trials of quizartinib monotherapy in patients (pts) with FLT3 -ITD–mutated (mu) relapsed/refractory (R/R) AML with or without prior 1st-generation FLT3 tyrosine kinase inhibitors (TKI) treatment.
